Annual prevalence of GLP-1 RA use among US adults without diabetes increased from 0.1% in 2018-2021 to 0.4% in 2022, with an estimated 854,728 adults without diabetes taking these medications.

That still represents a minute fraction of the estimated 23,000 out of every 100,000 teens in the country who are living with obesity, and is far slower than the uptake among U.S. adults.